Cancer cells often develop resistance to chemotherapy and ferroptosis by stabilizing NRF2 through KEAP1 inactivation or genetic alterations in the NRF2 pathway, with NRF2 overexpression associated with poor outcomes in primary malignant brain tumors[98,99]. The gene discussed is KEAP1; the disease is cancer.